CliffBio
small molecule

VELSIPITY

ETRASIMOD ARGININE

Loss of exclusivityJune 2036latest FDA-listed patent expiry
CompanyPfizer →See this company's full patent-cliff portfolio

Drug detail

Brand nameVELSIPITY
Active ingredientETRASIMOD ARGININE
StrengthEQ 2MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2023
Marketing statusRX

Listed patents

PatentExpiresType
10676435June 2036use U-3731
10301262June 2036substance, product
11884626June 2036use U-3731
11091435June 2036substance, product
12377071January 2036use U-4255
11007175January 2036use U-3730
12156866January 2036use U-4047
8580841March 2030substance, product
9126932July 2029use U-3732

Regulatory exclusivity

CodeExpires
NCEOctober 2028

More from Pfizer

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VELSIPITY patent cliff — loss of exclusivity June 2036 | CliffBio